Quantitative spatial profiling of PD-1/PD-L1 and TIGIT/CD155 interaction indicates poor survival outcome and resistance to adjuvant chemotherapy in pancreatic adenosquamous carcinoma

Gastrointestinal Cancer

Immunohistochemical expression of PD-L1 in colorectal carcinoma among black patients and the clinicopathological correlates: a cross-sectional study

BMC Gastroenterol

Menkiti FE, Okani CO, Onyiaorah IV, Ukah CO, Menkiti IO, Ihekwoaba EC, Okoye OA, Ofiaeli OC, Akpuaka FC

doi: 10.1186/s12876-025-03862-7

Hepatology

Elevated CircYthdc2 expression is correlated with aggressive features and poor progression-free survival in hepatocellular carcinoma

BMC Gastroenterol

Gong Y, Li X, Wang M

doi: 10.1186/s12876-025-04231-0

Gastrointestinal Cancer

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Adv Ther

Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH

doi: 10.1007/s12325-025-03133-7

Gastrointestinal Cancer

Evaluation of PINK1 protein expression as a predictive marker for the efficacy of adjuvant chemotherapy in colorectal cancer: a retrospective study

BMC Gastroenterol

Fujii T, Hirasaki M, Kamakura Y, Kawasaki T, Yamasaki S, Ishiyama Y, Hiranuma C, Hamaguchi T, Hirano Y, Sakuramoto S

doi: 10.1186/s12876-025-04197-z

Gastrointestinal Cancer

Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial

Lancet Gastroenterol Hepatol

Schouten TJ, Prinsze KJ, Henry AC, Daamen LA, Besselink MG, Bonsing BA, Bosscha K, Busch OR, Cirkel GA, van Dam RM, van Eijck CH, Festen S, Groot Koerkamp B, van der Harst E, de Hingh IHJT, Kazemier G, Liem MSL, de Meijer VE, Sven D Mieog J, Patijn GA, Roos D, Schreinemakers JMJ, Stommel MWJ, Wit F, van Werkhoven CH, Molenaar IQ, Smits FJ, van Santvoort HC, Dutch Pancreatic Cancer Group

doi: 10.1016/S2468-1253(25)00367-X

Gastrointestinal CancerHepatology

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

J Hepatol

Yopp A, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Cha E, Hack SP, Lian Q, Spahn J, Wu C, Qin S, Chow PK

doi: 10.1016/j.jhep.2026.01.006

Gastrointestinal Cancer

Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Am J Gastroenterol

Hwang SY, Rezaee-Zavareh MS, Attia AM, Kaymen EA, Tran N, Abou-Alfa GK, Parikh ND, Singal AG, Yang JD

doi: 10.14309/ajg.0000000000003546

Gastrointestinal Cancer

Diagnostic value of peripheral blood inflammatory indices for clinicopathological profile of colorectal cancer: a retrospective observational study

BMC Gastroenterol

Rezazadeh M, Kamyabi A, Pisheh RG, Noroozie S, Amiri BS, Negahi A, Radkhah H

doi: 10.1186/s12876-025-03681-w

Hepatology

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study

Hepatology

Tovoli F, Iavarone M, Cabibbo G, Marra F, Vivaldi C, Dalbeni A, Ponziani FR, Palloni A, Bergamo F, Rimassa L, Lani L, Federico P, Svegliati-Baroni G, Ielasi L, Mazzarelli C, De Lorenzo S, Sacco R, Bruccoleri M, Celsa C, Mastro A, Masi G, Auriemma A, Stella L, Toniutto P, Villani R, Lonardi S, Pressiani T, Piscaglia F, ARTE study group

doi: 10.1097/HEP.0000000000001725

Related content

Immunohistochemical expression of PD-L1 in colorectal carcinoma among black patients and the clinicopathological correlates: a cross-sectional study

Elevated CircYthdc2 expression is correlated with aggressive features and poor progression-free survival in hepatocellular carcinoma

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Evaluation of PINK1 protein expression as a predictive marker for the efficacy of adjuvant chemotherapy in colorectal cancer: a retrospective study

Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Diagnostic value of peripheral blood inflammatory indices for clinicopathological profile of colorectal cancer: a retrospective observational study

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study